**8. Conclusions**

As new antiplatelet and anticoagulant drugs have entered the therapeutic arsenal, and as stent platforms continue to be refined through the years, established dogmas of the treatment of patients with ischemic heart disease should be reassessed. Most notably, current evidence strongly supports that for a considerable number of patients, shorter antithrombotic, aspirin-free treatment is associated not only with fewer bleeding complications, but with comparable rates of hard ischemic endpoints. Hence, a paradigm shift is underway, in which the concern should not be to find reasons to reduce the classical 12 months of DAPT. Rather, patients should be evaluated for causes *not to* receive an abbreviated aspirin-free antithrombotic


#### **Table 4.**

*Recent trials on the performance of different stent platforms on shortened DAPT scenarios.*

*Dual Antiplatelet Therapy after PCI: When Could We Go Shorter? DOI: http://dx.doi.org/10.5772/intechopen.96328*

regimen. In order to provide the most accurate treatment regimens, a careful evaluation should be made by taking into account the clinical presentation, coexisting conditions that are prone to a higher ischemic or bleeding risk and awareness of the stent platform used.
